US 11,884,906 B1
4D-perfused tumoroid-on-a-chip platform for personalized cancer treatment applications
Subhra Mohapatra, Lutz, FL (US); Shyam S. Mohapatra, Lutz, FL (US); and Tao Wang, Tampa, FL (US)
Assigned to University of South Florida, Tampa, FL (US)
Filed by University of South Florida, Tampa, FL (US)
Filed on Mar. 2, 2023, as Appl. No. 18/116,550.
Application 18/116,550 is a division of application No. 16/799,413, filed on Feb. 24, 2020, granted, now 11,685,885.
Claims priority of provisional application 62/809,305, filed on Feb. 22, 2019.
Int. Cl. C12M 3/06 (2006.01); B01L 3/00 (2006.01); C12M 1/32 (2006.01); C12M 1/12 (2006.01); G01N 33/50 (2006.01); C12M 1/34 (2006.01); C12N 5/09 (2010.01)
CPC C12M 23/16 (2013.01) [B01L 3/502715 (2013.01); C12M 23/12 (2013.01); C12M 25/14 (2013.01); C12M 41/26 (2013.01); C12M 41/36 (2013.01); C12N 5/0693 (2013.01); G01N 33/5011 (2013.01); B01L 2300/0627 (2013.01); B01L 2300/0819 (2013.01); B01L 2300/0829 (2013.01); C12N 2503/02 (2013.01); C12N 2513/00 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method of anticancer drug screening, the method comprising the steps of:
adding a plurality of target cells onto a fiber inspired smart scaffold to a culture well of a microfluidic platform, the microfluidic platform comprising
a plate including a plurality of bottomless wells coupled to a chip insert including a plurality of bioreactors by inserting the chip insert below the plate, such that the plurality of bioreactors are in communication with the plurality of bottomless wells, each of the plurality of bioreactors including a culture well in fluidic communication with each of an inlet well and an outlet well;
adding a first amount of a culture media to the inlet well, adding a second amount of the culture media to the culture well, and adding a third amount of the culture media to the outlet well, the first amount being greater than each of the second amount and the third amount;
flowing the culture media from the inlet well toward the outlet well via the culture well due to the difference in volume between the inlet well and the outlet well;
after approximately 48 hours, adding an amount of a testing drug to the fiber inspired smart scaffold; and
quantifying viability of the plurality of target cells after the amount of the testing drug is added to the scaffold;
wherein a decreased number of the plurality of target cells on the fiber inspired smart scaffold is indicative of decreased viability and potential efficacy of the testing drug.